GleamWall
中文EN

CELU Celularity Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1752828 · Fiscal year ends 12/31

Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY4.5%
TTM net income YoY34.7%
TTM EPS YoY43.2%
Revenue 3-yr CAGR21.0%
Net income 3-yr CAGR—

Margins

Gross margin55.1%
Operating margin-105.8%
Net margin-165.2%
FCF margin—
EBITDA margin-90.8%

Returns

ROE-6,367.2%
ROA-57.6%
ROIC (approx.)—
Asset turnover0.35x

Leverage & solvency

Liabilities / assets121.2%
Debt / equity—
Current ratio0.25x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.03x
Accruals ratio-55.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue$5.43M$3.85M$4.10M$5.28M$5.74M$11.43M$18.13M$9.30M
Cost of revenue$2.35M$1.45M$7.37M$3.90M$5.24M$3.55M$7.34M$3.88M
Gross profit$3.08M$2.39M-$3.27M$1.38M$494,000$7.87M$10.79M$5.41M
R&D expense$2.03M$2.99M$3.35M$4.60M$3.35M$3.73M$3.83M$3.92M
SG&A expense$4.94M$9.16M$15.06M$9.31M$12.63M$14.26M$16.06M$12.65M
Operating income-$4.24M-$10.13M-$22.06M-$12.90M-$15.86M-$10.49M-$9.28M-$11.53M
Interest expense$177,000$352,000——$1.94M$2.44M——
Pretax income$706,000$874,000-$24.36M-$23.08M-$24.52M-$19.75M-$13.29M-$16.10M
Income tax———————$0
Net income$706,000$874,000-$24.36M-$23.08M-$24.52M-$19.75M-$13.29M-$16.10M
EBITDA-$3.05M-$8.54M-$20.25M-$11.45M-$14.40M-$8.65M-$7.40M-$10.01M
EPS (basic)0.020.02—-0.88-1.02-0.84—-0.73
EPS (diluted)0.020.02—-0.88-1.02-0.84—-0.73
Weighted avg. shares (diluted)29.34M30.30M—26.35M24.02M23.53M—21.98M
Balance sheet
Cash & equivalents$586,000$368,000$6.17M$120,000$10.94M$10.30M$10.98M$10.33M
Receivables$4.68M$4.78M$4.65M—————
Inventory$718,000$477,000$571,000$2.56M$4.41M$6.20M$5.41M$3.96M
Current assets$6.45M$6.30M$12.32M$10.60M$17.26M$22.08M$20.56M$14.50M
PP&E, net$53.38M$54.57M$55.80M$57.22M$58.67M$60.13M$61.60M$63.21M
Goodwill$7.35M$7.35M$7.35M$7.35M$7.35M$7.35M$7.35M$7.35M
Intangibles$6.33M$7.39M$7.76M$8.13M$8.51M$8.88M$9.25M$9.62M
Total assets$96.17M$99.48M$107.33M$114.24M$120.28M$128.88M$132.68M$128.84M
Current liabilities$59.74M$70.58M$80.76M$65.31M$69.23M$58.69M$53.68M$76.17M
Short-term debt————$6.30M$6.30M—$42.61M
Long-term debt——$33.81M$35.67M————
Total debt——$33.81M$35.67M————
Total liabilities$131.70M$134.74M$145.39M$134.33M$145.78M$134.38M$123.84M$111.56M
Shareholders' equity-$35.53M-$35.26M-$38.06M-$20.09M-$25.50M-$5.51M$8.84M$17.28M
Net debt——$27.64M$35.55M————
Shares outstanding29.28M29.18M28.84M28.22M24.61M23.94M22.55M21.98M
Cash flow statement
Operating cash flow-$1.11M$1.45M-$5.10M-$4.16M-$999,000-$2.99M$1.59M-$144,000
Capital expenditure——————$56,000$35,000
Free cash flow——————$1.54M-$179,000
Investing cash flow——————-$1.56M-$35,000
Financing cash flow$1.02M-$7.34M$11.22M$3.48M$1.63M$2.32M$643,000-$79,000
Depreciation & amortization$1.18M$1.60M$1.80M$1.45M$1.46M$1.83M$1.88M$1.52M
Stock-based compensation$844,000$1.24M$9.85M$471,000$2.45M$2.64M$2.94M$2.67M

Free plan shows the latest 8 periods; Pro shows all 30 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.